10 Most Undervalued Stocks to Buy for Under $10

3. Clarivate (NYSE:CLVT)  

Number of Hedge Fund Investors: 27  

Forward P/E Ratio as of October 8: 8.83 

Stock Price as of October 8: $6.57  

Clarivate (NYSE:CLVT) is a leading global provider of information and analytics services, catering to the research and intellectual property sectors. Formed in 2016 from the combination of Thomson Reuters’ Intellectual Property & Science and Financial & Risk businesses, Clarivate (NYSE:CLVT) is headquartered in London and operates in over 40 countries.

Clarivate (NYSE:CLVT) focuses on subscription-based services, ensuring consistent revenue streams and solidifying its position in the data-driven services industry. In Q2, Clarivate’s (NYSE:CLVT) Academic and Government (A&G) segment saw strong organic growth, with subscription revenues increasing by over 3%, alongside a renewal rate exceeding 96%. The Intellectual Property segment also showed improvement, with organic growth rising 270 basis points, signaling stabilization in trademark search volumes. However, the Life Sciences & Healthcare segment faced slower growth due to a weak macroeconomic environment, but analysts expect a strong rebound in FY25 as pharmaceutical companies restart their R&D efforts.

On September 23, Clarivate (NYSE:CLVT) announced a strategic partnership with Relatable Healthcare to introduce a Product Relationship Management (PRM) platform for MedTech companies. This platform integrates Clarivate’s competitive intelligence with Relatable’s software to offer a unified source of product information, driving revenue growth and efficiency for medtech manufacturers and distributors by providing access to detailed product data, cross-references, inventory, and sales materials.

Clarivate’s (NYSE:CLVT) stock trades at a forward P/E ratio of 8.83, reflecting a significant 56.16% discount to the sector median of 20.14.